Multiple regulatory aspects of histone methyltransferase EZH2 in Pb-induced neurotoxicity

被引:4
|
作者
Xue, Wei-Zhen [1 ]
Gu, Xiaozhen [1 ]
Wu, Yulan [1 ]
Li, Danyang [1 ]
Xu, Yi [1 ]
Wang, Hui-Li [1 ]
机构
[1] Hefei Univ Technol, Sch Food Sci & Engn, Hefei 230009, Anhui, Peoples R China
基金
美国国家科学基金会;
关键词
Pb; neurotoxicity; EZH2; chromatin immunoprecipitation; PRC2; DEVELOPING HIPPOCAMPAL-NEURONS; LEAD-EXPOSURE; CELL-DIFFERENTIATION; SPINAL-CORD; METHYLATION; H3K27ME3; TRANSCRIPTION; MECHANISMS; EXPRESSION; DISORDERS;
D O I
10.18632/oncotarget.19615
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pb is a pervasive environmental threat to human health. Although remarkable progress has been made in its neurotoxicity, the precise molecular mechanisms underlying this widespread toxicant still remain elusive. In this study, the detailed roles of EZH2, a transcriptional repressor, in the regulation of Pb-led neurotoxicity were investigated, highlighting its sub-functionalization, compartmentalization, functional chaperones and downstream partners. Based on the findings, EZH2's protein levels were significantly reduced in response to Pb treatment; EZH2' s gain-of-function trials recovered the dampened neurite outgrowth; EZH2' recruitment to ploycomb complex, as well as its interaction with cytosolic Vav1, was altered in a distinct manner, suggesting that EZH2' s multiple roles were markedly redistributed in this context; EZH2' s cytosolic and nuclear presence differed in their respective response towards Pb treatment; EZH2 directly occupied the promoters of EGR2, NGFR and CaMKK2, genes responsible for various nerve functions and repair mechanisms, and essentially contributed to their aberrant expression. It indicated that EZH2 mediated the dynamic changes of a cascade of key molecules and consequently the related neurological impairments. In summary, EZH2 emerges as a central player to regulate Pb-led neurotoxicity in a transcriptionally dependent and independent manner, and thereby provided a promising molecular target for medical intervention.
引用
收藏
页码:85169 / 85184
页数:16
相关论文
共 50 条
  • [1] Regulatory Roles of Histone Deacetylases 1 and 2 in Pb-induced Neurotoxicity
    Wu, Yulan
    Xu, Yi
    Huang, Xiyao
    Ye, Danlei
    Han, Miaomiao
    Wang, Hui-Li
    TOXICOLOGICAL SCIENCES, 2018, 162 (02) : 688 - 701
  • [2] Expression of the histone methyltransferase EZH2 in colorectal cancer
    Carvalho, S. Dias
    Monteiro-Reis, S.
    Vieira-Coimbra, M.
    Pires-Luis, A.
    Tavares, A.
    Santos, L. L.
    Raimundo, A.
    Jeronimo, C.
    Henrique, R.
    VIRCHOWS ARCHIV, 2016, 469 : S4 - S4
  • [3] Targeting histone methyltransferase EZH2 as cancer treatment
    Kondo, Yutaka
    JOURNAL OF BIOCHEMISTRY, 2014, 156 (05): : 249 - 257
  • [4] Substrate preferences of the EZH2 histone methyltransferase complex
    Martin, C
    Cao, R
    Zhang, Y
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (13) : 8365 - 8370
  • [5] The role of histone methyltransferase EZH2 in myelodysplastic syndromes
    Xu, Feng
    Li, Xiao
    EXPERT REVIEW OF HEMATOLOGY, 2012, 5 (02) : 177 - 185
  • [6] Expression of Histone Methyltransferase EZH2 in Ovarian Cancer
    Leitner, K.
    Wieser, V
    Tsibulak, I
    Knoll, K.
    Koegl, J.
    Reimer, D.
    Marth, C.
    Fiegl, H.
    Zeimet, A. G.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2020, 80 (04) : 432 - 433
  • [7] Roles of the EZH2 histone methyltransferase in cancer epigenetics
    Simon, Jeffrey A.
    Lange, Carol A.
    MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2008, 647 (1-2) : 21 - 29
  • [8] Inhibition of the Histone Lysine Methyltransferase EZH2 for the Treatment of Cancer
    Verma, Sharad K.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2015, 15 (08) : 714 - 719
  • [9] Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer
    Jones, Bayley A.
    Varambally, Sooryanarayana
    Arend, Rebecca C.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (03) : 591 - 602
  • [10] Role of the EZH2 histone methyltransferase as a therapeutic target in cancer
    Italiano, Antoine
    PHARMACOLOGY & THERAPEUTICS, 2016, 165 : 26 - 31